Progress on new vaccine strategies against chronic viral infections
about
Modulation of antigen-specific T-cells as immune therapy for chronic infectious diseases and cancerViral Vaccines and CTL ResponseEngineering antigen-specific T cells from genetically modified human hematopoietic stem cells in immunodeficient mice.Interference of retroviral envelope with vaccine-induced CD8+ T cell responses is relieved by co-administration of cytokine-encoding vectors.Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool.A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein.Characterization of the specific CD4+ T cell response against the F protein during chronic hepatitis C virus infectionIncreased immunogenicity of HIV-1 p24 and gp120 following immunization with gp120/p24 fusion protein vaccine expressing alpha-gal epitopesA conserved E7-derived cytotoxic T lymphocyte epitope expressed on human papillomavirus 16-transformed HLA-A2+ epithelial cancers.Strategies to use immune modulators in therapeutic vaccines against cancerImmunization delivered by lentiviral vectors for cancer and infectious diseases.Construction and characterization of chimeric BHIV (BIV/HIV-1) viruses carrying the bovine immunodeficiency virus gag gene.Protective capacity of memory CD8+ T cells is dictated by antigen exposure history and nature of the infectionPhytol-based novel adjuvants in vaccine formulation: 2. Assessment of efficacy in the induction of protective immune responses to lethal bacterial infections in mice.Possible therapeutic vaccine strategy against human immunodeficiency virus escape from reverse transcriptase inhibitors studied in HLA-A2 transgenic miceNon-equilibrium and differential function between intraepithelial and lamina propria virus-specific TCRalphabeta(+) CD8alphabeta(+) T cells in the small intestinal mucosa.Vaccination of cats with attenuated feline immunodeficiency virus proviral DNA vaccine expressing gamma interferonInhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitisImpact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa.The role of models in understanding CD8+ T-cell memory.Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease.HIV-1(89.6) Gag expressed from a replication competent HSV-1 vector elicits persistent cellular immune responses in miceIntensified and protective CD4+ T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccineAdenovirus as vehicle for anticancer genetic immunotherapy.Optimal blood mononuclear cell isolation procedures for gamma interferon enzyme-linked immunospot testing of healthy Swedish and Tanzanian subjects.Delivery systems and adjuvants for oral vaccines.Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization.Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsetsA new era in HIV vaccine development.Chimeric HBcAg virus-like particles presenting a HPV 16 E7 epitope significantly suppressed tumor progression through preventive or therapeutic immunization in a TC-1-grafted mouse model.Vaccination sequence effects on immunological response and tissue bacterial burden in paratuberculosis infection in a rabbit model.Bloodborne viral hepatitis infections among drug users: the role of vaccinationStrategies for optimizing targeting and delivery of mucosal HIV vaccines.Fabrication of nanoadjuvant with poly-ε-caprolactone (PCL) for developing a single-shot vaccine providing prolonged immunity.Enhancing immunogenicity and cross-reactivity of HIV-1 antigens by in vivo targeting to dendritic cells.Past speculations of future health technologies: a description of technologies predicted in 15 forecasting studies published between 1986 and 2010.Immune deficiency in HIV-1 infection: novel therapeutic approaches targeting innate and adaptive responses.Increased immunogenicity of human immunodeficiency virus gp120 engineered to express Galalpha1-3Galbeta1-4GlcNAc-R epitopes.Fms-like tyrosine kinase 3 receptor ligand (Flt3L)-based vaccination administered with an adenoviral vector prevents tumor growth of colorectal cancer in a BALB/c mouse model.Could therapeutic vaccination of cytomegalovirus-seropositive persons prevent reinfection and congenital virus transmission?
P2860
Q27022761-08D08E68-5B60-4F50-8DDC-D6B0D7985D4CQ27491330-2A9E8C5F-61FC-46A1-BF57-7277304D75A8Q30974719-BB65B524-01D4-4478-9D10-29FD55476893Q33613835-7728E461-A347-4CB0-AF7B-A6B901C4C29AQ33736534-9401F1C7-69C2-4EFC-A4FB-21C265981C8BQ33743790-4140CD34-8846-4164-BC9C-440B723F13FFQ33769438-A049CA26-A373-4DCF-9AD7-7F9884A0C890Q33837215-DA7AC49B-794F-4CC3-ABC1-7DA5B6BF782BQ34121681-220F3075-DC4F-4047-B0F9-71786E06FBD7Q34275601-1AFDA817-566E-4E75-8E14-7D0E2B2E21C6Q34539879-3CCB5412-0225-4EA9-904D-29D15DA69D7DQ35010631-8E95538F-3043-4BDA-9E4A-240CAA41789DQ35012041-0E1FE53C-B376-4645-892B-D1F1641A295FQ35125351-2BBACAD9-9E2A-47A0-99C3-161C2DAC0E6CQ35139305-A8F03733-55E3-41C1-BCF5-8EC6E86D71ADQ35575565-915525E8-64F3-40FA-AA96-31B09C3FAD84Q35634943-0CAA00E9-395C-4BAE-A2BB-44C1DC603CAAQ35848218-622B841B-50DB-48CE-82C2-8564F13C5888Q35849596-768C5072-1FB5-412B-866E-82C5A00686C0Q36015867-49C0B4C8-B84B-4908-9BA0-18E396C7CDD2Q36108119-B076358A-FCFA-4357-8902-1770A9ED4D83Q36156347-5853DF71-8DED-433C-A392-EE1612F9947CQ36228405-1888A522-1336-4441-A29B-DED5A7FC4E30Q36288930-36448558-5266-481E-9C8E-66AB4AEEC82AQ36539081-FE879C44-1D05-4EBD-8AE5-653B462C14B2Q36640326-D695CE0C-11B0-4E82-B23E-A001C45A2CAEQ36663607-B8924AEA-044E-4A35-A1F1-4394DFA9174EQ36742299-64079455-E140-482D-8333-2423ED911748Q36777835-A843298F-108E-4B2B-8A7A-9DB135A37900Q36967911-85AD6BE4-9D4A-43CF-ABA6-896EF676C41AQ37156509-5FB84DB7-AC7B-46F3-A242-8C5E63F5BFBCQ37167103-492F3220-0096-4DE9-AD70-D8CBDB503015Q37554135-3303E219-B0FA-4FDB-A71E-8DF0A6A255D0Q37591932-3B6A2B5B-85A5-4EB1-BB0C-65379FEE3DB2Q38059499-24FF155E-0BCA-453E-93EA-A0DE98C92223Q38649073-0C80AE2E-1D35-4B42-8840-8D60C173F4FCQ40377124-D9A03EBA-AD6E-4F69-960B-F178BA082D97Q41495119-D81F013B-56FE-43E5-BC1A-BAC8998A2F88Q42263453-7DCFBDB0-5633-446A-9425-35810E8DECEDQ42735574-D28B0511-FA30-4914-86A0-A5693E86A49E
P2860
Progress on new vaccine strategies against chronic viral infections
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Progress on new vaccine strategies against chronic viral infections
@ast
Progress on new vaccine strategies against chronic viral infections
@en
type
label
Progress on new vaccine strategies against chronic viral infections
@ast
Progress on new vaccine strategies against chronic viral infections
@en
prefLabel
Progress on new vaccine strategies against chronic viral infections
@ast
Progress on new vaccine strategies against chronic viral infections
@en
P2093
P2860
P356
P1476
Progress on new vaccine strategies against chronic viral infections
@en
P2093
Igor M Belyakov
Jay A Berzofsky
Jeffrey D Ahlers
John Janik
John Morris
Masaki Terabe
SangKon Oh
P2860
P304
P356
10.1172/JCI200422674
P407
P577
2004-08-01T00:00:00Z